Lecigon (Entacapone, Levodopa, Carbidopa Monohydrate)

Levodopa is converted to dopamine in the brain, restoring deficient neurotransmission. Carbidopa blocks peripheral conversion of levodopa, allowing more to reach the brain. Entacapone inhibits the COMT enzyme, slowing levodopa breakdown and extending its plasma half‑life, which together provide smoother symptom control.

The dose of Lecigon is individualized. A qualified prescriber determines the appropriate strength, frequency and total daily amount based on the patient’s clinical condition, response to therapy and tolerability.

Safety of Lecigon in pregnancy or lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician.

To request Lecigon, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lecigon combines a COMT inhibitor (entacapone) with levodopa/carbidopa, offering longer levodopa exposure than levodopa/carbidopa alone. Compared with dopamine agonists, it provides a more direct dopamine replacement but may have a higher risk of dyskinesia. Choice depends on individual patient needs and physician assessment.

Lecigon tablets should be stored at room temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Lecigon is taken orally, usually with food to reduce gastrointestinal upset. The tablets are swallowed whole with a glass of water. The exact timing and frequency are prescribed by the treating clinician.

Serious risks include severe hypotension, neuroleptic malignant syndrome, liver toxicity, severe allergic reactions, and worsening psychiatric symptoms such as depression or suicidal thoughts. Patients should be monitored closely for these events, and any concerning signs should prompt immediate medical evaluation.

Lecigon is contraindicated in patients taking non‑selective MAO inhibitors, those with narrow‑angle glaucoma, or individuals with known hypersensitivity to any component of the product. Caution is also advised for patients with severe cardiovascular disease, liver impairment, or a history of psychiatric disorders.